Transcription
Welcome to another video, yet again. So, you can see on my last upload, you can see in the top right, I called out MSS, Mason Solutions, when it was trading just around $1 per share. And if you look on the chart, you can see that this one just hit highs of $1.92 for just over a 100% gainer. So, drop a quick like for me on this video if you are enjoying this content, and make sure you have that notification bell turned on because these plays can be extremely time-sensitive. And also, make sure that you subscribe to the channel if you haven't already.
But, in this video, I will be presenting an extremely rare penny stock within the healthcare sector. There's no dilution available right now, and this is a company that has never conducted a reverse stock split. You can see since 2016, they have pretty much not even changed the outstanding share count. You know, it's barely went up since then. They're cash flow positive, and this is a company with a 4 million share float that has real revenue coming in. You know, I believe around $30 million in yearly revenue coming in, and the chart is looking completely bottomed out. Historically, this one always does run from this level just based on the previous price action.
But, keep in mind that trading penny stocks is extremely risky, and anything can happen with these plays. Nothing is ever guaranteed, and I'm not a financial advisor or anything like that. So, you always have to go out and do your own homework and your own research before even looking at any of these extremely volatile stocks. But, in my opinion, I do believe that this company is severely undervalued because their revenue has been consistently going up since 2021. They have been profitable, you know, most of the years since that time period. Now, for 2024 and 2025, their revenue basically stayed the same year over year. But, you can see they have been profitable for the last it looks like the last, you know, 4 years not including the most recent fiscal year, they did lose uh $1.6 million in that profit, but they have had a consistent history of revenue growth and profitability. And for a healthcare company, that is extremely rare, and considering that this one is sitting under a $10 million market cap, doing this much revenue, and having, you know, millions of dollars of cash in the bank with, you know, way more assets than their valuation, I do believe this one is on discount.
So, the stock I'm talking about for this video is American Shared Hospital Services, which trades under ticker AMS, and you can see on the daily timeframe, this one is looking to be completely bottomed out, curling off the bottom. We know we have a triple or quadruple bottom right here, and this one historically does tend to run from this level, like I already mentioned. You can see market cap is sitting around $9.1 million. 52-week low is around $1.25, so we are pretty close to that area. 52-week high is sitting at $3.11, according to WeBull. The free float is sitting at 3.5 million shares, according to WeBull. The average volume over the last 3 months is only sitting at 176,000 shares traded. As the biggest resistance levels on the major timeframes are sitting at $1.50, $1.75, and just around that $2 area. So, those are some key levels to watch out for.
American Shared Hospital Services provides turnkey technology solutions for advanced radio surgical and radiation therapy services. AMS is a world leader in providing gamma knife radio surgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia, which is a form of face pain. Plus, the company also offers proton therapy and the latest IGRT, IMRT, and MR/LINAC systems. You can see historically they have a very low dilution risk. They have never really diluted more than, you know, 1 or 2 million shares since 2016. And as of right now, according to Dilution Tracker, there are no open dilution filings. The company is cash flow positive based on quarterly operating cash flow of $2.15 million. Looking at their most recent filings, you can see that they haven't really had any insiders sell any shares directly on the market basically in over 2 years. So, considering this one is sitting near the 52-week low, I do not believe insider selling is a concern, especially considering that they did not sell any shares back when this one spiked to $1.75 multiple times and to just over $2 just over 1 month ago. So, I do not believe insider selling is a concern with this company. Insiders do currently hold around 25% of the total outstanding share count. But like I said, I do not believe this will be a concern.
And on their balance sheet, you can see they do have $5.2 million cash in the bank, according to the most recent financials that came out. Total assets are sitting at $54.7 million. So, if you compare that to their $9 market cap, they are severely undervalued just based off that, and that's not even including their revenue capabilities. Um looking at their total liabilities, this is sitting at $28 million, but only $4.2 million of that is in long-term debt. So, they basically have double their current liabilities in assets, which is really nice to see, you know, especially for a biotech company. Um for the most recent quarter, they did do around $7.1 million in total revenue. They did lose $600,000. So, very minimal net loss for this entire year so far. Have shown in the past that they are capable of showing consistent profitability like they have from, you know, 2021 all the way to 2024 or yeah, basically 2021 and 2024 had a small net loss or, you know, just around $1.6 million net loss in 2025. As of lately, the margins have been going down and the revenue growth has stalled year-over-year, but I still believe that this one is still very undervalued at the current price and sitting around this tiny $10 million market cap.
So, going on Alpha Spread using this calculator, which is a stock valuation platform that uses proven and scientific-based valuation methods to automatically estimate the intrinsic value of stocks, you can see AMS has an intrinsic value of $2.12, which is, you know, way higher than the current stock price right now. On their website, guys, looking on their presentation, you can see that ASHS is a leading provider of creative financial and turnkey solutions to cancer treatment centers, hospitals, and large cancer networks worldwide. The company works closely with major global original equipment manufacturers, OEMs, that provide leading edge clinical treatment systems and software to treat cancer using radiation therapy and radio surgery. Major products the company is able to provide financial support for include MR-guided radiation therapy, LINACs, advanced digital linear accelerators, proton beam therapy systems, brachytherapy systems. Through the company's GK financing partnership with Elekta, the Leksell Gamma Knife product and services, ASHS is a leading global provider of Gamma Knife radiosurgery equipment, which I've already talked about. So, their purpose is to finance medical equipment, but not in traditional terms. They make the best medical technology accessible to you via innovative models. They are also doing their fair share of delivering critical equipment in underserved markets, and they are very proud of their achievements. Basically, they give their clients, hospitals, and clinics the means and the resources to take on and combat deadly diseases. They do offer financial services for a wide variety of equipment. It does look like they have a very experienced management team, so that's really good to see. And that's really all I have for this stock, and I will be making some more videos soon. So, let me know in the comments what you think about this play and any other plays you're watching, and I will see you on the next video.